Clinical Trial Update: Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating vorinostat in combination with chemotherapy and rituximab for HIV-related and other aggressive B-cell lymphomas; trial completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids-related Plasmablastic Lymphoma
• Aids-related Primary Effusion Lymphoma
• Diffuse Large B-cell Lymphoma
• Effusion Lymphoma
• Follicular Lymphoma
• HIV Infection
• Non-contiguous Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-06-12